Richter extends cariprazine licensing deal to Japan, Taiwan
Image by LaMography/Móni Lázár
Hungarian pharmaceutical company Gedeon Richter on Wednesday announced the extension of a licensing agreement with U.S. peer AbbVie for its antipsychotic cariprazine to Japan and Taiwan, according to a report by state news wire MTI.
Under the terms of the agreement, AbbVie is responsible for development and commercialisation of cariprazine for certain neuropsychiatry indications in Japan. Richter is eligible for a milestone payment after the drug's approval there, along with tiered royalties and sales-related milestone payments to follow.
Richter's licensing agreement for cariprazine with AbbVie, originally dated 2004, covered the territories of the United States and Canada. It was extended in 2019 to include certain countries in Latin America.
Cariprazine, marketed under the brand names Vraylar and Reagila, is Richter's second best-selling product after oral contraceptives.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.